Ocular's experimental eye drug beats Regeneron's low-dose Eylea in a Phase 3 clinical trial. Ocular plans to seek FDA approval. It is not clear whether doctors and insurance companies will favor this new drug. The study compared the effectiveness of drugs in eye diseases. The main finding is the superiority of the experimental drug over low-dose Eyle. The article does not provide specific statistics or numbers from the results.